Opening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells

doi:10.1016/j.ccell.2020.01.005

Cancer Cell

Volume 37, Issue 2, 10 February 2020, Pages 139-140

https://doi.org/10.1016/j.ccell.2020.01.005 Get rights and content

Under an Elsevier user license

open archive

PARP inhibition (PARPi) kills tumor cells defective in homologous recombination-based repair (HR−) but not their HR+ competent counterparts. In this issue of Cancer Cell, it is shown that, when EZH2 is functionally silenced, HR+, CARM1-high, high-grade serous ovarian cancer cells become PARPi sensitive, undergo mitotic catastrophe, and die.

Cancer Cell

PreviewOpening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells

Preview
Opening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells